Literature DB >> 2732124

Treatment of chronic osteomyelitis with ciprofloxacin.

J A Hoogkamp-Korstanje1, H A van Bottenburg, J van Bruggen, J S Davidson, S J Detmar, W de Graaf, J Rijnks, J F Ypma, D F de Zwart.   

Abstract

Twenty-seven patients with chronic osteomyelitis were treated with oral ciprofloxacin, 500 mg (13 patients) or 750 mg (13) twice daily and one patient was treated with 300 mg twice daily intravenously. Treatment was given for 17-189 days (mean 69). Twenty-three patients had prosthetic implants, 16 patients had infections caused by one bacterium and 11 had polymicrobial infections. The predominant organisms were strains of Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. Cure was obtained in 20 patients and improvement in four. Three patients failed to respond to therapy. Concentrations of ciprofloxacin, measured in pus 1 h after 500 mg orally ranged from 0.6-1.3 mg/l, whilst 2 h after 750 mg orally concentrations of 2.4-6.8 mg/l were found. Sterilization of pus and closure of infected wounds or draining sinuses were observed within four weeks of treatment in the majority of patients. Ciprofloxacin was well tolerated in 26 patients, whilst one had severe nausea after oral administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2732124     DOI: 10.1093/jac/23.3.427

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Use of quinolones in osteomyelitis and infected orthopaedic prosthesis.

Authors:  D P Lew; F A Waldvogel
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 2.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

Review 3.  Quinolones and osteomyelitis: state-of-the-art.

Authors:  D P Lew; F A Waldvogel
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 4.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.